Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Savolitinib in Recurrent, Progressive, or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations

NCT03598244 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03598244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03598244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Savolitinib in Recurrent, Progressive, or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 27, 2018
Completion date
May 27, 2027
Enrollment
41 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse intrinsic pontine glioma, recurrent malignant glioma, recurrent medulloblastoma, recurrent primary central nervous system neoplasm, refractory diffuse intrinsic pontine glioma, refractory malignant glioma, refractory medulloblastoma, refractory primary central nervous system neoplasm